免疫调节策略,以减少静脉静脉复缩
Mei Yu1, Chengyi Dai1, Jingjing Shi2
1The Xiaoshan Hospital Affiliated to Wenzhou Medical University, Hangzhou, 310201, China.
Biomaterials science
|August 4, 2025
概括
在支架植入后,支架内缩 (ISR) 是一个复杂的问题. 新的"免疫友好型"支架旨在通过调节免疫反应和促进血管愈合来减少ISR.
科学领域:
- 心血管生物学 心血管生物学
- 免疫学 免疫学 免疫学
- 生物材料科学 生物材料科学
背景情况:
- 支架内静止症 (ISR) 是支架植入后的一个重大并发症.
- 由于复杂的免疫和炎症反应,目前的支架技术难以完全预防ISR.
- 需要新的策略来调节免疫活动并增强血管愈合.
研究的目的:
- 审查ISR背后的免疫媒介机制.
- 探索目前和新兴的免疫调节方法来预防ISR.
- 评估下一代支架在缓解ISR方面的潜力.
主要方法:
- 关于ISR的临床前和临床研究的文献综述.
- 分析免疫细胞 (中性粒细胞,巨细胞) 在新极度增生和炎症中的作用.
- 免疫调节策略的评估:支架表面修改,药物输送和先进的支架设计.
主要成果:
- 像中性粒细胞和巨细胞这样的免疫细胞是ISR中新极度增生和慢性炎症的关键驱动因素.
- 免疫调节方法,包括表面修饰和生物活性分子输送,显示出有希望.
- 内皮模仿性支架提供了平衡促修复和抗炎信号的潜力.
结论:
- 开发"免疫友好型"支架对于减轻ISR至关重要.
- 综合免疫学和生物材料的跨学科战略是必不可少的.
- 下一代支架通过管理免疫反应,有望改善临床结果.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
509
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
509
Atherosclerosis III: Management
35
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
35
Mitral Stenosis III: Medical Management
21
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
21
Peripheral Artery Disease III: Interprofessional Care
29
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
29
Myocarditis III: Medical Management
16
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
16
Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23


